1.21

0.82% -0.01

After Hours: 1.24 0.03 +2.48%

NeuroSense Therapeutics Ltd (NRSN)

Overview News Price History Discussions Forecast

NeuroSense Therapeutics Ltd stock is currently priced at $1.21, with a 24-hour trading volume of 79,982. It has seen a -0.82% decreased in the last 24 hours and a -24.38% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.21 pivot point. If it approaches the $1.24 resistance level, significant changes may occur.

Previous Close:

$1.22

Open:

$1.2

24h Volume:

79,982

Market Cap:

$20.97M

Revenue:

Net Income/Loss:

$-11.48M

P/E Ratio:

-0.938

EPS:

-1.29

Net Cash Flow:

1W Performance:

+2.54%

1M Performance:

-24.38%

6M Performance:

+127.87%

1Y Performance:

-30.46%

1D Range:

$1.16

$1.285

52W Range:

$0.40

$2.33

NeuroSense Therapeutics Ltd Stock (NRSN) Company Profile

Name

NeuroSense Therapeutics Ltd

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 9 799 6183

Address

Building B, 11 HaMenofim Street, Herzliya

Employee

Twitter

Next Earnings Date

2024-05-25

Latest SEC Filings

NRSN's Discussions on Twitter

NeuroSense Therapeutics Ltd Stock (NRSN) Latest News

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning - PR Newswire

PR Newswire

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically ... - Marketscreener.com

Marketscreener.com

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically ... - Nasdaq

Nasdaq

NeuroSense Therapeutics Ltd Stock (NRSN) Financials Data

NeuroSense Therapeutics Ltd (NRSN) Net Income 2024

NRSN net income (TTM) was -$11.48 million for the quarter ending September 30, 2023, a -23.56% decrease year-over-year.

NeuroSense Therapeutics Ltd (NRSN) Earnings per Share 2024

NRSN earnings per share (TTM) was -$0.94 for the quarter ending September 30, 2023, a -16.16% decline year-over-year.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.